In men with @ nocturnal voids at baseline , @ and @ % of patients with silodosin and placebo had reductions of @ voids/night , respectively ( p = @ ) , and significantly more patients with silodosin had < @ nocturia episodes at study end compared to placebo ( @ vs. @ % ; p = @ ) .